MOLBIO

Molbio Diagnostics Limited

Molbio Diagnostics Limited (MOLBIO) financial statements and selected valuation metrics through 30 June 2026.

Healthcare›Healthcare›Healthcare Equipment & Supplies›Medical Equipment & Supplies

Ask AI

Key metrics

Price as of 2026-10-22

Stock price
₹1259.70
Market cap
14,517 Cr
Stock P/E
85.3 · FY26
P/B
12.15
ROE (FY26)
12.7%
ROCE (FY26)
15.4%
Operating margin (FY26)
17.8%
Debt / equity (FY26)
0.35
OCF / EBITDA (FY26)
15.7%
OCF / EBITDA (3Y)
42.4%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Molbio Diagnostics makes Truenat, a battery-operated, portable machine and test kits that run molecular (gene-based) tests such as tuberculosis (TB) in about 60 minutes at clinics far from a laboratory, selling mainly to government health programmes in India and to distributors abroad.

Company snapshot

2ndBy market cap

Ranked among 8 companies in Medical Equipment & Supplies.

What we see

Positives
  • ✓Revenue grew 42% in the latest year — strong top-line momentum.
Concerns
  • ✗Only 42% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricJun 2026
Sales408 Cr
Operating expenses (approx.)308 Cr
EBITDA101 Cr
OPM %24.6%
Other income3 Cr
Interest11 Cr
Depreciation17 Cr
Profit before tax76 Cr
Tax %30.5%
Net profit53 Cr
EPS (₹)₹5.21

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2024Mar 2025Mar 2026TTM
Sales837 Cr1,020 Cr1,446 CrSign in free for the trailing twelve months
Operating expenses (approx.)602 Cr758 Cr1,124 CrSign in free for the trailing twelve months
EBITDA234 Cr262 Cr321 CrSign in free for the trailing twelve months
OPM %28.0%25.7%22.2%Sign in free for the trailing twelve months
Other income4 Cr8 Cr9 CrSign in free for the trailing twelve months
Interest14 Cr18 Cr33 CrSign in free for the trailing twelve months
Depreciation41 Cr45 Cr64 CrSign in free for the trailing twelve months
Profit before tax130 Cr194 Cr231 CrSign in free for the trailing twelve months
Tax %35.6%28.7%29.0%Sign in free for the trailing twelve months
Net profit84 Cr139 Cr164 CrSign in free for the trailing twelve months
EPS (₹)₹9.05₹12.87₹14.77Sign in free for the trailing twelve months
Dividend payout %———Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2024Mar 2025Mar 2026
Equity capital2 Cr2 Cr11 Cr
Reserves821 Cr966 Cr1,158 Cr
Borrowings175 Cr123 Cr413 Cr
Other liabilities218 Cr371 Cr427 Cr
Total liabilities1,221 Cr1,462 Cr2,148 Cr
Fixed assets (net)168 Cr204 Cr248 Cr
CWIP2 Cr27 Cr11 Cr
Investments6 Cr46 Cr6 Cr
Inventories315 Cr436 Cr449 Cr
Trade receivables425 Cr272 Cr409 Cr
Cash & bank22 Cr115 Cr356 Cr
Other assets283 Cr362 Cr670 Cr
Total assets1,221 Cr1,462 Cr2,148 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2024Mar 2025Mar 2026
Cash from operating activity10 Cr287 Cr50 Cr
Cash from investing-45 Cr-123 Cr-93 Cr
Cash from financing-32 Cr-26 Cr276 Cr
Net cash flow-67 Cr138 Cr233 Cr
Free cash flow (OCF − Capex)-34 Cr232 Cr0.79 Cr

Ratios

MetricMar 2024Mar 2025Mar 2026
ROCE %14.4%19.4%15.4%
ROE %12.3%15.0%12.7%
Debtor days18697103
Inventory days360365287
Days payable107193127
Cash conversion cycle438269262
OCF / EBITDA %4.1%109.5%15.7%
OCF / EBITDA % (3 years)——42.4%
Debt / equity0.210.130.35
Current ratio2.402.112.48
Net debt / EBITDA0.650.030.18